230 related articles for article (PubMed ID: 28924735)
1. The G protein-coupled estrogen receptor (GPER/GPR30) may serve as a prognostic marker in early-stage cervical cancer.
Friese K; Kost B; Vattai A; Marmé F; Kuhn C; Mahner S; Dannecker C; Jeschke U; Heublein S
J Cancer Res Clin Oncol; 2018 Jan; 144(1):13-19. PubMed ID: 28924735
[TBL] [Abstract][Full Text] [Related]
2. Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer.
Sjöström M; Hartman L; Grabau D; Fornander T; Malmström P; Nordenskjöld B; Sgroi DC; Skoog L; Stål O; Leeb-Lundberg LM; Fernö M
Breast Cancer Res Treat; 2014 May; 145(1):61-71. PubMed ID: 24715381
[TBL] [Abstract][Full Text] [Related]
3. GPER Overexpression in Cervical Cancer Versus Premalignant Lesions: Its Activation Induces Different Forms of Cell Death.
Hernandez-Silva CD; Riera-Leal A; Ortiz-Lazareno PC; Jave-Suárez LF; Ramírez De Arellano A; Lopez-Pulido EI; Macías-Barragan JG; Montoya-Buelna M; Dávila-Rodríguez JR; Chabay P; Muñoz-Valle JF; Pereira-Suárez AL
Anticancer Agents Med Chem; 2019; 19(6):783-791. PubMed ID: 30727915
[TBL] [Abstract][Full Text] [Related]
4. G-protein-coupled estrogen receptor GPER-1 expression in hormone receptor-positive breast cancer is associated with poor benefit of tamoxifen.
Ignatov T; Claus M; Nass N; Haybaeck J; Seifert B; Kalinski T; Ortmann O; Ignatov A
Breast Cancer Res Treat; 2019 Feb; 174(1):121-127. PubMed ID: 30478785
[TBL] [Abstract][Full Text] [Related]
5. Estrogen-mediated inactivation of FOXO3a by the G protein-coupled estrogen receptor GPER.
Zekas E; Prossnitz ER
BMC Cancer; 2015 Oct; 15():702. PubMed ID: 26470790
[TBL] [Abstract][Full Text] [Related]
6. The G-protein coupled estrogen receptor (GPER/GPR30) is a gonadotropin receptor dependent positive prognosticator in ovarian carcinoma patients.
Heublein S; Mayr D; Vrekoussis T; Friese K; Hofmann SS; Jeschke U; Lenhard M
PLoS One; 2013; 8(8):e71791. PubMed ID: 23951246
[TBL] [Abstract][Full Text] [Related]
7. Elevated expression of G protein-coupled receptor 30 (GPR30) is associated with poor prognosis in patients with uterine cervical adenocarcinoma.
Ino Y; Akimoto T; Takasawa A; Takasawa K; Aoyama T; Ueda A; Ota M; Magara K; Tagami Y; Murata M; Hasegawa T; Saito T; Sawada N; Osanai M
Histol Histopathol; 2020 Apr; 35(4):351-359. PubMed ID: 31483053
[TBL] [Abstract][Full Text] [Related]
8. GPR30, the non-classical membrane G protein related estrogen receptor, is overexpressed in human seminoma and promotes seminoma cell proliferation.
Chevalier N; Vega A; Bouskine A; Siddeek B; Michiels JF; Chevallier D; Fénichel P
PLoS One; 2012; 7(4):e34672. PubMed ID: 22496838
[TBL] [Abstract][Full Text] [Related]
9. The G protein-coupled estrogen receptor (GPER) is expressed in two different subcellular localizations reflecting distinct tumor properties in breast cancer.
Samartzis EP; Noske A; Meisel A; Varga Z; Fink D; Imesch P
PLoS One; 2014; 9(1):e83296. PubMed ID: 24421881
[TBL] [Abstract][Full Text] [Related]
10. Continuous Exposure of Breast Cancer Cells to Tamoxifen Upregulates GPER-1 and Increases Cell Proliferation.
Molina L; Bustamante F; Ortloff A; Ramos I; Ehrenfeld P; Figueroa CD
Front Endocrinol (Lausanne); 2020; 11():563165. PubMed ID: 33117280
[TBL] [Abstract][Full Text] [Related]
11. Expression and Role of the G Protein-Coupled Estrogen Receptor (GPR30/GPER) in the Development and Immune Response in Female Reproductive Cancers.
Hernández-Silva CD; Villegas-Pineda JC; Pereira-Suárez AL
Front Endocrinol (Lausanne); 2020; 11():544. PubMed ID: 32973677
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of G Protein-Coupled Estrogen Receptor (GPER) is Associated with Reduced Prognosis in Patients with Gastric Cancer.
Tian S; Zhan N; Li R; Dong W
Med Sci Monit; 2019 Apr; 25():3115-3126. PubMed ID: 31028714
[TBL] [Abstract][Full Text] [Related]
13. Female Sex Hormone Receptor Profiling in Uterine Adenosarcomas.
Marcus JZ; Klobocista M; Karabakhtsian RG; Prossnitz E; Goldberg GL; Huang GS
Int J Gynecol Cancer; 2018 Mar; 28(3):500-504. PubMed ID: 29303935
[TBL] [Abstract][Full Text] [Related]
14. G protein-coupled estrogen receptor (GPER) mediates NSCLC progression induced by 17β-estradiol (E2) and selective agonist G1.
Liu C; Liao Y; Fan S; Tang H; Jiang Z; Zhou B; Xiong J; Zhou S; Zou M; Wang J
Med Oncol; 2015 Apr; 32(4):104. PubMed ID: 25744245
[TBL] [Abstract][Full Text] [Related]
15. GPR30 predicts poor survival for ovarian cancer.
Smith HO; Arias-Pulido H; Kuo DY; Howard T; Qualls CR; Lee SJ; Verschraegen CF; Hathaway HJ; Joste NE; Prossnitz ER
Gynecol Oncol; 2009 Sep; 114(3):465-71. PubMed ID: 19501895
[TBL] [Abstract][Full Text] [Related]
16. Plasma membrane expression of G protein-coupled estrogen receptor (GPER)/G protein-coupled receptor 30 (GPR30) is associated with worse outcome in metachronous contralateral breast cancer.
Tutzauer J; Sjöström M; Bendahl PO; Rydén L; Fernö M; Leeb-Lundberg LMF; Alkner S
PLoS One; 2020; 15(4):e0231786. PubMed ID: 32302351
[TBL] [Abstract][Full Text] [Related]
17. GPER-1/GPR30 a novel estrogen receptor sited in the cell membrane: therapeutic coupling to breast cancer.
Molina L; Figueroa CD; Bhoola KD; Ehrenfeld P
Expert Opin Ther Targets; 2017 Aug; 21(8):755-766. PubMed ID: 28671018
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of eukaryotic initiation factor 5A2 (EIF5A2) is associated with cancer progression and poor prognosis in patients with early-stage cervical cancer.
Yang SS; Gao Y; Wang DY; Xia BR; Liu YD; Qin Y; Ning XM; Li GY; Hao LX; Xiao M; Zhang YY
Histopathology; 2016 Aug; 69(2):276-87. PubMed ID: 26799253
[TBL] [Abstract][Full Text] [Related]
19. GPER Promoter Methylation Controls GPER Expression in Breast Cancer Patients.
Weissenborn C; Ignatov T; Nass N; Kalinski T; Dan Costa S; Zenclussen AC; Ignatov A
Cancer Invest; 2017 Feb; 35(2):100-107. PubMed ID: 28118074
[TBL] [Abstract][Full Text] [Related]
20. G Protein-Coupled Estrogen Receptor Correlates With Dkk2 Expression and Has Prognostic Impact in Ovarian Cancer Patients.
Fraungruber P; Kaltofen T; Heublein S; Kuhn C; Mayr D; Burges A; Mahner S; Rathert P; Jeschke U; Trillsch F
Front Endocrinol (Lausanne); 2021; 12():564002. PubMed ID: 33679613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
